Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Trovafloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 1/20 | 0.98 |
| ▸ | FLT4 | P35916 | 1/20 | 0.98 |
| ▸ | GSK3B | P49841 | 1/20 | 0.98 |
| ▸ | RARB | P10826 | 1/20 | 0.98 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.98 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.98 |
| ▸ | LMNA | P02545 | 4/20 | 0.88 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.88 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.88 |
| ▸ | HPGD | P15428 | 2/20 | 0.88 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.88 |
| ▸ | POLB | P06746 | 2/20 | 0.88 |
| ▸ | XBP1 | P17861 | 1/20 | 0.88 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.88 |
| ▸ | HTT | P42858 | 1/20 | 0.88 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.88 |
| ▸ | RELA | Q04206 | 1/20 | 0.88 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.76 |
| ▸ | DPP4 | P27487 | 6/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trovafloxacin SCHEMBL7688507 | 1.00 | EPHA2 (0.98) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Trovafloxacin SCHEMBL29711175 | 1.00 | EPHA2 (0.98) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Trovafloxacin SCHEMBL29384064 | 0.99 | EPHA2 (1.00) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Trovafloxacin SCHEMBL34465 | 0.99 | EPHA2 (1.00) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Trovafloxacin SCHEMBL13575805 | 0.99 | EPHA2 (1.00) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Trovafloxacin SCHEMBL34466 | 0.99 | EPHA2 (1.00) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Trovafloxacin SCHEMBL9177464 | 0.99 | EPHA2 (1.00) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Trovafloxacin SCHEMBL29688441 | 0.99 | EPHA2 (1.00) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Trovafloxacin SCHEMBL20769811 | 0.99 | EPHA2 (1.00) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Trovafloxacin SCHEMBL1902266 | 0.99 | EPHA2 (1.00) | EPHA2FLT4GSK3BRARBTBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2023-04-20 | — | — | US | disclosed |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | ASCENDIS PHARMA A/S (DE) | 2023-01-24 | — | — | US | disclosed |
| EP-4011396-A1 | RELEASABLE CONJUGATES | QuiaPEG Pharmaceuticals AB (SE) | 2022-06-15 | — | — | EP | disclosed |
| US-6359137-B1 | ANTIBIOTIC | PFIZER INC. | 2002-03-19 | — | — | US | disclosed |
| EP-0989119-A1 | Process and intermediates for preparing trovafloxacin acid salts | Pfizer Products Inc. (US) | 2000-03-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | EPHA2 1154/4885FLT4 59/4885GSK3B 800/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | EPHA2 383/4885FLT4 2670/4885GSK3B 2400/4885 |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | PLG, PHYKPL, PLOD3 | EPHA2 1154/4885FLT4 59/4885GSK3B 800/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | EPHA2 383/4885FLT4 2670/4885GSK3B 2400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.